Key insights from head and neck research at ASCO 2025

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Key insights from lung cancer research at ASCO 2025

ASCO 2025: Importance of early testing in metastatic prostate cancer

ASCO 2025: Highlights and analysis

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC

Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma

ASCO 2025: Metastatic breast cancer treatment highlights

ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer

Disparities in mammogram screening amongst LGBTQ+ populations

Ropeginterferon Alfa-2b shows superior efficacy over anagrelide in essential thrombocythaemia

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC

Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer

New MOAs in prostate cancer treatment - what’s next?

AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers

Long-term infusion of dinutuximab beta improves survival in high-risk neuroblastoma

Relacorilant plus chemo improves PFS and OS vs chemo alone in platinum-resistant ovarian cancer

Barriers to global oncology clinical trial participation in sub-Saharan Africa

Social determinants and survival outcomes in early-onset colorectal cancer in the US

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

Rusfertide shows promise for polycythemia vera treatment

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma

ASCO 2025: Update on blood-based cancer assays

Trastuzumab deruxtecan benefit for some advanced gastric cancers

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer

Abemaciclib potential therapeutic option for Kaposi sarcoma

Making immune check point inhibitors for lung cancer cost-effective in LMICs

ASCO 2025: Latest in EGFR positive NSCLC

Ecological evaluation of climate risks for cancer survivors

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

Sacituzumab govitecan helps postpone progression in some PD-L1-positive triple-negative breast cancer patients

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Characteristics associated with longer-term OS with NALIRIFOX regimen in metastatic pancreatic adenocarcinoma

Pro-inflammatory diets associated with worse outcomes for stage III colon cancer

Exercise programme may lower risk of recurrence and death for some colon cancer survivors

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received perioperative durvalumab

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2-negative mBC

Adjuvant temozolomide improves survival in IDH-mutant anaplastic glioma

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers